MS Views and News – a Patient Advocacy Organization that provides educational information for ALL affected by Multiple Sclerosis

Being Empowered with MS information IS beneficial.

Visit our archived education program video recordings. Visit www.youtube.com/msviewsandnews

Visit our website: MS Views and News.org

joomla ecommerce template

Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information

.

==================================

Monday, October 8, 2012

Ampyra's worth, being questioned by an insurance carrier

Last week  I posted information regarding AETNA insurance company's decision to stop paying for an MS Medication. I also mentioned that if we did not stop this from happening that other companies might begin doing the same thing... And today I read this:


Acorda sinks after insurance provider questions MS drug
Theflyonthewall.com via Yahoo! Finance Mon, 08 Oct 2012 08:41 AM PDT


Acorda Therapeutics (ACOR) is retreating after Group Health, which provides health insurance to over 600,000 people in the Northwest, questioned the necessity of the company's multiple sclerosis treatment, ... 



THIS IS B.S.  everybody and we need to Voice our concerns.

IF the FDA approved the medications, then they must have found worth in the drug(s)

Click here to read the blog posting about Aetna and Then, Call Aetna to voice your resentment to their decision. The phone numbers are found at that posting.

..


2 comments:

steve s said...

I agree. FDA approves ampyra but insurance company doubts the efficacy????? Unfortunately, never a dull moment in MS treatment. MS treatments and policy is like the wild west.....anything is possible.

Stephany Richardson said...

volomeThe problem is big pharma thinks the sky is the limit for what they can charge for these drugs. It is a fight between big pharma and the insurance companies with us in the middle. But when you complain about an insurance company not paying for a drug, look at the cost.